Mesenchymal Tumor is an indication for drug development with over 80 pipeline drugs currently active. According to GlobalData, preregistered drugs for Mesenchymal Tumor have a 83.33% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Mesenchymal Tumor compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mesenchymal Tumor overview
Mesenchymal tumors are tumors developing from mesenchymal tissues. These tissues are made of cells including fibroblasts, nerve cells, blood vessel cells, muscle cells, and others. Benign soft tissue tumors are common in humans, but cancerous mesenchymal tumors are rare. Many tumors can originate from various cells, and the treatment mainly depends on the tumor’s type, severity, and aggressiveness. These are soft tissue tumors that occur due to any aberrancy during the developmental differentiation of mesenchymal tissue into fat, skeletal muscle, peripheral nerves, blood vessels, and fibrous tissues. One possible cause is mutations in genes that code for proteins controlling cell division. Having a family history of soft tissue tumors also increases the risk, but most mesenchymal tumors develop without any apparent risk factors.
For a complete picture of PTSR and LoA scores for drugs in Mesenchymal Tumor, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
